Navigation Links
The Diabetes Series 2008: Experts Speak About Developing Diabetes Therapeutics
Date:2/25/2008

SAN DIEGO, Feb. 25 /PRNewswire/ -- Speid & Associates, a San Diego-based regulatory affairs and drug development consultancy, is hosting a six session Webinar series on diabetes and related metabolic diseases during the months of March and April. Speakers will include former Food and Drug Administration officials Dr. Alexander Fleming and Dr. Ray Lipicky, as well as a distinguished list of other guest speakers and panelists.

Researchers and companies involved in diabetes therapeutic development are finding a complex array of possible targets across diabetes (both type 1, type 2), the metabolic syndrome, and the complications and causes of diabetes. This translates into a complex pathway for therapeutic development and registration with many potential pitfalls along the way. The webinar series will promote discussion on the inter-related issues of diabetes/metabolic therapeutic development and registration.

Dr. Speid said, "I am delighted that the series will feature such a stellar list of speakers, to address these important topics and issues." Dr. Alexander Fleming, ex-FDA (formerly headed diabetes drug review) said, "There is no more active and controversial therapeutic development area than for diabetes drugs. I look forward to discussing the implications of the ACCORD trial and a number of other timely topics."

For many years, Dr. Ray Lipicky headed FDA's Division of Cardiorenal Drug Products. Among his many drug approvals was the first and essentially only approval of treatments for a diabetic complication. The participation of Drs. Lipicky and Fleming in this series mirrors the convergence of cardiovascular and metabolic therapeutics at multiple levels -- pathophysiology, drug targets, trial design, and clinical disciplines.

Speid & Associates, Inc. is a regulatory affairs and drug development consultancy based in San Diego, Calif. The firm, founded in 2004 by Dr. Lorna Speid, Ph.D., assists life science companies at various stages in the drug development process. Speid's services, which vary from building global regulatory strategies to conducting due diligence for possible drug acquisitions, save large and small pharmaceutical firms from costly mistakes. Dr. Speid began her career as a pharmacist in the UK, after which she completed a Ph.D. at the Centre for Medicines Research International, into the Safety Assessment of Medicines, Pre and Post Marketing. Before forming her own consultancy, Dr. Speid worked for Sanofi Winthrop in the UK, Ciba Geigy and Novartis in Switzerland (HQ). Dr. Speid also worked for a number of small pharmaceutical companies, two of them at the Vice President level. For more information, see http://www.sndtm.com.

Further information regarding the webinar series is available at: http://www.sndtm.com/webinar.html as well as sign up instructions.

Telephone 858 793 1295. Email lspeid@sndtm.com.


'/>"/>
SOURCE Speid & Associates, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Vaccines are Likely to Cause Insulin Dependent Diabetes in Over 2% of Children With a Strong Family History of Insulin Dependent Diabetes, New Data Indicates
2. Good Neighbor Pharmacy(R) Ironman Competitor Inspires Individuals with Diabetes to Live Without Limits
3. Genaera Corporation to Participate in Diabetes and Obesity Panel at RBC Capital Markets Healthcare Conference
4. GlaxoSmithKline Responds to JAMA Article on the ICES Thiazolidinediones and Cardiovascular Outcomes in Older Patients with Diabetes
5. Novo Nordisk Applauds Adoption of World Diabetes Day Resolutions by U.S. Congress
6. International Diabetes Experts Call for Stepped-Up Action and Shared Responsibility to Curb Rising Global Diabetes Epidemic and Impact
7. World Think Tank on Type 1 Diabetes Meets in Miami
8. New Web Site Tools Help Alleviate Stress Associated with Caring for Children with Diabetes During the Holidays
9. Actress Aida Turturro Tells Americans to Start Now to Talk With Their Healthcare Provider About Taking Control of Their Diabetes
10. SemBioSys to present insulin data at the Seventh Annual Diabetes Technology Meeting
11. John Timberlake, Valeritas Executive Vice President and General Manager, Named Executive of the Year by the Diabetes Foundation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... -- Biocom, the association representing the Southern California ... San Diego companies to Washington ... Advocacy Fly-In. Biocom Fly-In participants had the opportunity to meet ... Centers for Medicare and Medicaid Services (CMS), the National Institutes ... Susan Davis and Scott Peters to ...
(Date:2/11/2016)... Non-profit Consortium Aims to Generate Genomic ... Research and Discovery --> --> ... plan to sequence 100,000 individuals. It is intended to initially ... 7 of North and East Asian countries. ... project will focus on creating phased reference genomes for all ...
(Date:2/11/2016)... BioPharma Selling Solutions (Spectra) is a new Contract ... experience, expertise, operational delivery and customer focus to ... in concert with industry leading commercial experts, the ... needs of its clients by providing value-based creative ... non-personal promotion. --> ...
(Date:2/11/2016)... , Feb. 11, 2016   BioInformant announces ... "Stem Cell Research Products, Opportunities, Tools, and Technologies – ... The ... the stem cell industry, BioInformant has more than a ... stem cell market, by stem cell type. This powerful ...
Breaking Biology Technology:
(Date:2/3/2016)... February 3, 2016 --> ... research report "Automated Fingerprint Identification System Market by Component ... Application (Banking & Finance, Government, Healthcare, and Transportation) and ... the market is expected to be worth USD 8.49 ... between 2015 and 2020. The transformation and technology evolution ...
(Date:2/2/2016)... 2016 This BCC Research report provides ... reviewing the recent advances in high throughput ‘omic ... field forward. Includes forecast through 2019. ... and opportunities that exist in the bioinformatic market. ... as well as IT and bioinformatics service providers. ...
(Date:2/2/2016)... 2016  Based on its recent analysis of ... US-based Intelligent Retinal Imaging Systems (IRIS) with the ... New Product Innovation. IRIS, a prominent cloud-based retinal ... , is poised to set the new ... market. The IRIS technology presents superior price-performance value ...
Breaking Biology News(10 mins):